Coherus Biosciences (CHRS) PT Lowered to $37 at Baird Following FDA Letter
Tweet Send to a Friend
Baird lowered its price target on Coherus Biosciences (NASDAQ: CHRS) to $37.00 (from $40.00) while maintaining a Outperform rating. Coherus ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
